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MRSAbstract Purpose: To demonstrate many advantages of using functional MRI in the assessment
of prostate cancer compared with traditional invasive TRUS-guided biopsy.
Patients and methods: This prospective study included 20 patients with clinical and laboratory (ele-
vated PSA level) suspicion of prostate cancer (age range 43–75 years, mean 65). Patients underwent
pretreatment functional MRI and TRUS-guided biopsy. MRI examinations were performed using
1.5-T MRI unit. The MRI protocol included T2WI, DWI, and MRS. TRUS-guided biopsy was
done with 9–12 MHz endocavitary transducer. The diagnostic performance of T2WI combined with
DWI and MRS was determined with histopathologic data from biopsy as the reference standard.
Results: Fifteen patients (75%) proved to have prostate cancer. Gleason score 8 was the most com-
mon (46.6%). Most of prostate lesions (17 patients) involved the peripheral zone. The ADCs were
signiﬁcantly lower in prostate cancer than in the prostatitis (p= 0.02). T2WI combined with DWI
and MRS had the highest diagnostic performance with a sensitivity, speciﬁcity and accuracy of
91.9%, 90.8%, and 88.2% respectively.
Conclusion: Functional MRI provided a highly sensitive method in diagnosing and localizing
prostate cancer. Being noninvasive, highly sensitive with wider spectrum in nearby pelvic organs
assessment in one imaging session, it may totally replace TRUS-guided biopsy.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate gland consists of several tubule-alveolar glandular
regions embedded into a connective tissue and smooth muscle
stroma. The McNeal model of zonal anatomy describes four
zones, three of which contain glandular tissue (peripheral zone,
transitional zone and central zone), fourth non-glandular zone
called anterior ﬁbro-muscular stroma (1,2). In clinical practice,
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together with that of BPH. In men over 40 years old,
asymptomatic BPH can be considered a physiological
ﬁnding (3).
Despite a preference in T2 weighted imaging to detect sus-
picious areas for biopsy guidance (4), it has been established
that T2 imaging is not accurate in localizing prostate carci-
noma (PCa), particularly in patients with a non-palpable
tumor at digital rectal examination (DRE) (5) and has limited
speciﬁcity, given the high number of benign PZ lesions with
low signal intensity, which often simulate cancer. T2 weighted
imaging also has low sensitivity as non-palpable tumors are
often iso-intense with parenchyma, thus, undetectable without
biopsies.
A recently developed multiparametric MRI approach that
combines anatomic T2-weighted imaging with functional data
appears to be one of the most promising techniques for
prostate cancer detection. The latest diagnostic consensus
statement by the European Society of Urogenital Radiology
(ESUR) recommends anatomic T2-weighted imaging
combined with at least two functional techniques: diffusion-
weighted imaging (DWI), dynamic contrast-enhanced MRI
(DCE-MRI), and optionally MR spectroscopy (6).
Diffusion-weighted imaging can add valuable information
about tissue at the cellular level to the information obtained
from conventional T1 and T2 weighted imaging (7). It provides
important information about the cellular status of normal and
pathologic tissue. Diffusion-weighted imaging provides an
important quantitative bio-physical parameter that can be
used to differentiate benign from malignant prostate tissue (8).
ADC mapping can increase the sensitivity (54–98%) and
speciﬁcity (58–100%) of MR imaging in detection of prostate
cancer when diffusion-weighted imaging is used in conjunction
with T2-weighted imaging (9). The ADC values in the central
gland increase with age, in association with the development of
BPH (10). Therefore, diagnosis of prostate cancer with ADC
measurements, especially in the central gland, may be less sen-
sitive in elderly patients (11).
As regarding to MRS, citrate is found in fairly high concen-
trations in healthy prostate epithelium and prostatic ﬂuid; it is
found in low concentrations elsewhere in tissue (12). The nor-
mal prostate has an MR spectrum with a prominent citrate
peak at 2.6 ppm. A decreased citrate level is found in prostate
cancer, as well as in prostatitis and hemorrhage (11). Choline
concentrations are increased in prostate cancer. Increased cho-
line signal or concentration is considered the spectroscopic
hallmark of cancer (13,14); however, it has also been found
in benign conditions of the prostate such as prostatitis (14).
The most commonly used MR spectroscopic method is the
point-resolved spectroscopy sequence (PRESS) (11).
2. Patients and methods
2.1. Patients
This study was approved by the ethics committee of our insti-
tution during the period between November 2013 and
December 2014. Twenty patients were included in this study.
They referred to the Radiology department, from Urology,
oncology departments and outpatient clinics. All patients were
clinically suspected as prostate cancer, by suspicious digitalrectal examination (old patients with clinically manifested hard
prostate, and nodularity of the posterior surface of the gland).
All the patients had elevated PSA level (normal level of PSA is
4 ng/ml). Patients with abnormal coagulopathy, local infec-
tion, MRI contra-indications (as pacemaker or claustropho-
bia), and previous prostatic biopsy in less than three months
duration were excluded from the study.
2.2. Trans-rectal ultrasound guided biopsy protocol
Ultrasonographic examination and ultrasound guided biopsy
of the prostate was performed to all the patients using GE
Healthcare, Logiq 5 pro ultrasound real-time unit with a
9–12-MHz endo-cavitary transducer. Biopsy gun and its dis-
posable needles, metallic needle guide (for ultrasound probe)
and long Chiba needle (for local anesthetic) are the essential
tools for the procedure.2.3. Patient preparation and biopsy procedure
The procedure is explained and written informed consent was
obtained for all patients. Prophylactic antibiotic should be
given (e.g. Ciproﬂoxacin). Cleansing rectal enemas are
performed before biopsy to reduce the risk of infection.
Inﬁltration of local anesthesia through Chiba needle into the
prostate capsule is done. A number of 8–10 tissue cores were
taken, performed bilaterally at the base, mid-gland and apex
of the peripheral zone. Suspicious hypo-echoic lesions should
be biopsied. In addition, targeted biopsies should be taken
from areas of abnormal MRI signal. Biopsy samples are
labeled according to their location and MRI suspected loca-
tions. Each biopsy sample should be placed in the correct
and accurately labeled sample container containing formalin
solution for histopathologic assessment.
2.4. MRI protocol
The MRI examinations were performed on a 1.5-T MRI unit
(Achieva, Philips Medical Systems, Koninklijke Philips
Electronics N.V) using 8 channel pelvic phased array coil,
and the MRI protocol includes the following:
1. T2WI axial, sagittal and coronal: main conventional
sequences to defect abnormal signals, turbo spin-echo
(TSE) images were obtained in three orthogonal planes
(TSE; R/effective TE, 2000/90; echo-train length) with a
512 · 512 matrix, 3-mm slice thickness, no gap, and a
14-cm ﬁeld of view; the total imaging time was 12 min.
2. DWI and ADC map:
(a) DWI: Echo-planar diffusion-weighted images
(TR/TE, 2500/69) with b values of 0, 500, 800 and
1000 s/mm2 were obtained transverse to the prostate
and parallel to the corresponding set of T2-weighted
images. Twelve 4-mm-thick slices (no intersection
gap; 20-cm ﬁeld of view; matrix size of 256 · 256 with
an image acquisition time of 1 min 24 s).
(b) ADC map: generated using the system software. In-
addition, CSI was performed over a single slice tran-
sverse to the prostate, using a thickness of 15 mm and
a 16 · 16 grid (voxel size, 8.75 · 8.75 · 15 mm3).
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10 · 10 · 10, Flip angle 90), Multi-voxel (3D PRESS 120
voxel size 14 · 12 · 12, Flip angle 90).
2.5. Statistical analysis
Data entry was done by SPSS version 17 and analyzed by the
same software. The sensitivity, speciﬁcity and overall accuracy
were calculated in comparison with the gold standard
(histopathology of the biopsied cores). The probability (p
value) of less than 0.05 was used as a cutoff point for all signif-
icant tests.
3. Results
This prospective study included 20 males, and their ages ran-
ged from 43 to 75 years (mean age was 65 years). The serum
level of PSA and free/total PSA ratio were estimated for all
patients. The calculated free/total PSA ratio was <25% in
prostate cancer patients (15), and >25% in patients with pro-
statitis (5) (Table 1).
All patients were subjected to trans-rectal ultrasound and
ultrasound guided biopsy, and 8–10 tissue cores were taken
and performed bilaterally at the base, mid-gland and apex of
the peripheral zone. Suspicious hypo-echoic lesions were also
biopsied. Histopathology of the biopsied cores was the gold
standard for the study. According to the histopathology results
there were 15 out of 20 (75%) patients proved to have prostate
cancer and remaining 5 patients (25%) proved to have
prostatitis.
The 15 patients that were proved by histopathology as hav-
ing prostate cancer were graded based on Gleason score. The
range of the tumor in Gleason score starts from 2 (1 plus 1
for the most well differentiated) to 10 (5 plus 5 for the most
dedifferentiated). Based on this scoring system, Gleason score
8 (4 plus 4) was the most common in this study representing
46.6% (Table 2).
The prostatic lesions were characterized by conventional
T2WI as regarding to their location, extension, and associatedTable 1 PSA value and ratio for the studied group (n= 20).
No. of
patients
Pathologic
type
Serum level
(mean) (ng/ml)
Free/total PSA
ratio (%)
20 Prostate cancer >9 <25
Prostatitis <18 >25
Table 2 Gleason score for the study group (prostate cancer)
(n= 15).
No. of patients Gleason score Patients Percentage (%)
15 3 + 4 3 20
4 + 3 3 20
4 + 4 7 46.6
4 + 5 1 6.7
5 + 4 1 6.7
5 + 5 0 0nodal and distant metastases. The majority of prostate lesions
involved the peripheral zone as it were encountered in 17 out
of 20 patients. Extra-prostatic capsular extension to adjacent
structure includes seminal vesicle in 8 patients, bladder base
in 7 patients, recto-prostatic angle in 6 patients, and NVB in
5 patients. Extension to more than one adjacent structure
was detected in more than one patient. Associated nodal
metastases were detected in 7 patients, and osseous metastases
in 3 patients. All the prostatic lesions (20 patients) exhibit low
signal intensity at T2WI (Table 3).
Mean ADC values were calculated for all prostate lesions in
peripheral and central zones. The central gland cancer tended
to show smaller ADCs than peripheral zone cancer; however,
this difference is statistically insigniﬁcant (p= 0.7).
Comparing mean ADC values of prostate cancer with that
of prostatitis revealed that the ADCs were signiﬁcantly lower
in both central and peripheral zone prostate cancer than in
the prostatitis (p= 0.02) (Table 4) (Figs. 1–4).
For more conﬁrmation, better improvement of prostate
cancer detection and pretreatment assessment, MR spec-
troscopy was also performed for all patients, using choline–
citrate (Cho/Cit) ratio as an indicator of malignancy. Based
on previously determined cutoff value, P1.07 cutoff value
was used for diagnosing prostate cancer by MRS (Fig. 5).
A structured reporting system (the ‘‘Prostate Imaging
Reporting and Data System,’’ or ‘‘PI-RADS’’) has a standard-
ized sub-score for each MRI sequence (T2WI, DWI, and
MRS); the sub-scores were summarized in a ﬁnal score that
ranges between 1 and 5. According to this PI-RADS scoring
system, PI-RADS category 5 was the most common category
in this study representing 35% (Table 5).
The diagnostic performance of T2WI alone, T2WI com-
bined with DWI, and T2WI combined with DWI and MRS
was compared for better detection of prostate cancer. The
pooled sensitivity, speciﬁcity and accuracy for T2WI alone
were 73.3%, 80.5%, and 78.4% respectively. For T2WI com-
bined with DWI a higher sensitivity, speciﬁcity and accuracy
were demonstrated (89.6%, 90.1%, and 86.3%) respectively.
The highest diagnostic performance was determined with the
use of T2WI combined with DWI and MRS, with a sensitivity,
speciﬁcity and accuracy of 91.9%, 90.8%, and 88.2% respec-
tively (Table 6).4. Discussion
To date, most prostate cancer patients are diagnosed based on
positive DRE, rising serum PSA, followed by a trans-rectal
ultrasound-guided needle biopsy (8–12 cores). This strategy
often over diagnoses low grade posterior lesions and under
diagnoses higher grade anterior lesions of the prostate (15–
17). In instances when a patient has a negative biopsy (gener-
ally more than one biopsy session), but there is a high clinical
suspicion based on increased PSA or persistently elevated
PSA, imaging with magnetic resonance imaging (MRI) is used
to detect prostate cancer, and guided biopsies (18–22).
T2-weighted magnetic resonance (MR) imaging has been
widely used for pretreatment work-up for prostate cancer,
but its accuracy for the detection and localization of prostate
cancer is unsatisfactory (23). In order to improve the diagnos-
tic performance of MRI, investigators have applied diffusion-
weighted imaging (DWI), dynamic contrast-enhanced (DCE)
Table 3 T2 characterization of the prostate lesions (regarding location, extension, nodal and distant metastases) (n= 20).
No. of patients Location Extra-prostatic capsular extension Nodal
metastases
Distant
metastases
Central Peripheral Seminal
vesicle
Bladder base Recto-prostatic
angle
NVB
20 3 17 8 7 6 5 7 3
Table 4 Mean ± SD (·103 mm2/s) ADC values of prostate
lesions (n= 20).
Pathologic type Mean ADC values (mm2/s) p value
Prostate cancer (n= 15) 0.89 ± 0.21 · 103 0.7
Peripheral (n= 12) 0.81 ± 0.26 · 103
Central (n= 3)
Prostatitis (n= 5) 1.08 ± 0.41 · 103 0.02
Note: ADC indicates apparent diffusion coefﬁcient. Signiﬁcance
was considered when p< .05.
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ing, monitoring of treatment effect, and guidance for prostate
biopsy (24).
The addition of these functional MRI techniques can pro-
vide metabolic information, display altered cellularity, and
aid in noninvasive characterization of tissue and tumor vascu-
larity (25,26). These techniques have not been implemented
broadly in daily clinical practice yet (26); therefore, it is of
practical interest to evaluate the diagnostic performance of
conventional and functional MRI images in the pretreatment
assessment of prostate cancer compared with the traditional
invasive trans-rectal ultrasound and biopsy in a trial to reduce
its use because it is an invasive technique, carries risks of com-
plications, and tends to miss tumors with false-negative results
that require repeated biopsies. Literatures reported that theFig. 1 (A) Axial T2WI at mid gland level shows hypointense area at
bulge, another hypointense nodular pattern seen at the central gland a
restriction of the peripheral zone abnormality with corresponding low
central gland abnormality. Histopathologic examination proved adenodetection rates of prostate cancer were 10–19% on repeat
TRUS-guided biopsy (27,28) and up to 59% on MRI-guided
biopsy after two negative TRUS-guided biopsy sessions (29).
Firstly, the serum level of PSA and free/total PSA ratio
were estimated for all patients. We found that the serum level
of PSA was elevated in both prostate cancer and prostatitis
and this is not surprising because PSA is not speciﬁc for can-
cer, and considerable overlap in serum PSA values exists
between cancer and benign diseases, notably prostatitis and
BPH (3). So we rely mainly on free/total PSA ratio. It calcu-
lates the ratio of PSA bound to proteins (most likely situation
in the serum) versus the free circulating PSA. BPH usually pro-
duces more free PSA levels, and prostate cancer produces more
bound PSA levels. Thus, cancer is suspected when the bound
PSA level is high and the free level is low. Catalona et al.
(30) reported that a >25% free PSA is associated with 8%
cancer risk, whereas a <10% free PSA with a 56% risk of
cancer.
Trans-rectal ultrasound and ultrasound guided biopsy was
performed to all patients and it proved that 15 out of 20 (75%)
patients had prostate cancer. Histological grading was per-
formed to these 15 patients with prostatic cancer using the
Gleason score which is an important prognostic factor.
Based on this scoring system, the tumors in this study were
ranged from 7 to 10, which were corresponding to G3-4
[(Poorly differentiated or undifferentiated (marked anaplasia)
(Gleason score of 7–10)]. Gleason score 8 (4 plus 4) was the
most common representing 46.6%. This was in agreement withthe peripheral zone at the right side (black arrow) with no contour
t left side (black arrow). (B and C) DWI and ADC show diffusion
ADC value (0.5 · 103 mm2/s), however with no restriction of the
carcinoma.
Fig. 2 (A) Axial T2WI at mid gland level shows an ill-deﬁned hypointensity (erased charcoal sign) seen involving the central zone at the
right side (black arrow), with no encroachment upon the peripheral zone. (B and C) DWI and ADC show diffusion restriction
corresponding to the signal abnormality at T2WI with decreased ADC value (0.9 · 103 mm2/s) compared with the contralateral side.
Histopathologic examination proved adenocarcinoma.
Fig. 3 (A) Axial T2WI at mid gland level shows asymmetrical hypointense signal seen at the peripheral zone at the right side (black
arrow) with contour bulge. (B and C) DWI and ADC show no diffusion restriction or ADC abnormality. Histopathologic examination
proved prostatitis.
Evaluation of patients with suspected prostate cancer 1187Li et al. (31) who reported that up to 43% of localized prostate
cancers were poorly or undifferentiated and that the incidence
of poorly differentiated cancer signiﬁcantly increased among
localized (8.0% per year) and regional stage (6.1% per year)
prostate cancers during 2004–2007.
Basically, T2WI was performed to detect and localize pros-
tate cancer and to determine the extra-capsular extension to
bladder wall, seminal vesicles, and neurovascular bundles.
Nodal and distant metastases were also evaluated using the
same pulse sequence. Prostate cancer was interpreted when a
low T2 signal intensity was seen replacing the normally high
T2 signal intensity in the peripheral zone. However, Wu
et al. (32) addressed the limitations of T2WI; he postulated
that the presence of decreased T2 signal intensity in the periph-
eral zone is of limited sensitivity, because some prostatetumors are isointense. This ﬁnding is also of limited speciﬁcity,
because there are other possible causes of low T2 signal inten-
sity in the peripheral zone, including hemorrhage, scarring,
prostatitis, atrophy, cryosurgery, hormonal therapy, and
effects of radiation therapy. Choi et al. (23) also demonstrate
further limitations of using T2WI alone; he reported that
T2WI has signiﬁcant limitations for depicting cancer in the
transitional and central zones, because cancer and normal tis-
sues both have low signal intensity on T2WI.
To improve the previously mentioned limitations of ana-
tomic T2WI additional functional MRI image was added
which is DWI. DWI provides an important quantitative bio-
physical parameter that can be used to differentiate benign
from malignant prostate tissue (8). Prostate cancer attains high
SI on DWI and a low signal on ADC map compared to normal
Fig. 4 (A and D) Axial T2WI at mid gland level and at iliac vessel level shows diffuse hypointensity seen involving the entire peripheral
zone with invasion of the central gland (long black arrows), no contour bulge. This is associated with two enlarged left internal iliac lymph
nodes (short black arrow). (B and E) DWI shows a global diffusion restriction of the whole peripheral zone as well as signiﬁcant diffusion
restriction of both enlarged left internal iliac lymph nodes (white arrow). (C and F) ADC maps show corresponding low signal with low
ADC value (0.6 · 103 mm2/s). Histopathologic examination proved adenocarcinoma with nodal metastases.
1188 M.M.M. Elian et al.prostate tissue (24). In our study we used a high b value of
1000 s/mm2 for the detection of prostate cancer. This was
based on and in accordance with a meta-analysis study, 2012
(32) which demonstrated that most of the included studies used
b values of 1000 s/mm2. Wu et al. (32) found that DWI using a
b value of 1000 s/mm2 in the detection of prostate cancer had
high pooled sensitivity and speciﬁcity, this can be attributed to
that at a high b value, and DWI represents the molecular dif-
fusion of water almost exclusively. The results of this study
revealed that the mean ADCs of prostate cancer were signiﬁ-
cantly lower compared with prostatitis (p= 0.02). This was
in agreement with Nagel et al. (33) who found that the median
ADCs of biopsy specimens with prostatitis were signiﬁcantly
higher compared with low- and high-grade PCa (p< .001)
and Esen et al. (34) who reported that the ADC values of pros-
tate cancer group were signiﬁcantly lower than normal pros-
tate and prostatitis group at b value of 600 and 1000 s/mm2
gradients. As regarding the anatomic location we found
insigniﬁcant difference between ADC values of prostate cancer
in either peripheral (0.89 ± 0.21 · 103) or central zone(0.81 ± 0.26 · 103), and this was coincided with Kim et al.
(35): in his study that included 47 cancer patients, the mean
ADC values were 0.99 ± 0.21 and 0.96 ± 0.14 for peripheral
and central zone cancer respectively.
The European Society of Urogenital Radiology (ESUR)
classiﬁcation, which was recently adopted by the American
College of Radiology (ACR), is the best available guideline
for using multiparametric MRI in the diagnosis of prostate
cancer (26). In addition to providing recommendations relat-
ing to indications and minimum standards for MR protocols,
the guideline describes a structured reporting scheme (PI-
RADS) based on the BI-RADS classiﬁcation for breast imag-
ing (36). In our study PI-RADS scoring system was applied to
improve the quality and diagnostic value of MRI in diagnosing
of prostate cancer, and the standardized sub-score for every
MRI sequence used in this study (T2WI, DWI, and MRS)
was combined into a ﬁnal total PI-RADS score. Our results
showed that PI-RADS class 5 was the most common class in
this study representing 35%. Class 5 (highly suspicious of
malignancy) denotes a hypo intense mass, that is round and
Fig. 5 (A and D) Axial T2WI at mid- and base-gland level shows diffuse hypointense area seen at the peripheral zone at the right side
(black arrow) and nodule of erased charcoal sign seen at the central gland at the left side. There is contour bulge with invasion of the right
neurovascular bundle as well as seminal vehicles (black arrow). This is associated with hypointense sclerotic bony lesion seen involving the
right pubic bone (yellow arrow). (B and E) DWI shows diffusion restriction of the peripheral zone lesion, the central gland nodule, as well
as the right pubic bony lesion (yellow arrow). (C and F) ADC maps show corresponding low signal with low ADC value (0.55 · 103 mm2/
s for the peripheral zone lesion and 0.67 · 103 mm2/s for the central gland nodule). (G) MR spectroscopy shows decreased citrate peak
(Ci), elevated choline peak (Cho) and increased Cho/Cr ratio (2.8). Histopathologic examination proved multicentric adenocarcinoma
with NVB and seminal vehicles invasion and distant (bony) metastases.
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Table 5 PI-RADS score of the prostate lesions (n= 20).
PI-RADS
classiﬁcation
Deﬁnition No. Percent
(%)
1 Most probably benign 0 0
2 Probably benign 4 20
3 Indeterminate 4 20
4 Probably malignant 5 25
5 Highly suspicious of
malignancy
7 35
Table 6 Diagnostic performance of T2WI alone, combined
T2WI and DWI, and combined T2WI, DWI and MRS for
localization and diagnosing of prostate cancer.
Diagnostic
performance
T2
WI
T2WI + DWI T2WI + DWI+MRS
Sensitivity (%) 73.3 89.6 91.9
Speciﬁcity (%) 80.5 90.1 90.8
Accuracy (%) 78.4 86.3 88.2
1190 M.M.M. Elian et al.bulging, with capsular involvement or seminal vesicle invasion
on T2WI, appears as a focal hyper intense mass on the DWI
image (bP 800 s/mm2) with reduced ADC value, and shows
signiﬁcantly elevated Cho compared to citrate on MRS.
In our study, the diagnostic performance of multiparamet-
ric MRI using anatomic T2WI combined with two additional
functional techniques: DWI and MRS were determined for
prostate cancer detection with histopathology of the biopsied
cores as the reference standard. The results of this prospective
study revealed a higher diagnostic performance for T2WI com-
bined with DWI and MRS (sensitivity, speciﬁcity and accuracy
of 91.9%, 90.8%, and 88.2%, respectively) than for T2WI
alone (73.3%, 80.5%, and 78.4%) and T2WI combined with
DWI (89.6%, 90.1%, 86.3%). This was in agreement with
other recent meta-analysis studies (26,32,37) which proved
the potential advantage of adding one or more functional
MRI technique to the anatomic T2WI for prostate cancer
detection.
Based on our results, the high sensitivity, speciﬁcity and
accuracy of functional imaging (T2WI, DWI and MRS) look
promising and even better compared to those of trans-rectal
sonography guided biopsy. First it aids the localization and
staging of the prostate cancer as a pretreatment step for the
coming surgical plan and adjuvant therapy, or for the second
step traditional trans-rectal biopsy allowing more accurate
localization and targeting of the suspicious lesions to reduce
the rate of reported false negative and false positive results.
Limitations of our study included relatively small patient
sample. A future study with larger population is recommended
to support the results of this study.
5. Conclusion
We concluded that the diagnostic performance of multi-
parametric MRI using anatomic T2WI combined with two
additional functional techniques: DWI and MRS provided a
much higher sensitivity than T2WI alone. It also provides a
non-invasive method in diagnosis and localization of prostatecancer that aids trans-rectal biopsy in targeting the suspected
lesions. By being noninvasive, wider spectrum in assessment
of the nearby pelvic organs in one imaging session, and its use-
fulness in patient post-treatment follow-up, is a one stop shop
imaging modality that may totally replace invasive trans-rectal
biopsy; however, more studies should be conducted in the
future to support this study.
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